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Abstract 
Heterozygous loss of function mutations in the type II bone morphogenetic protein receptor 
(BMPR-II), a member of the transforming growth factor (TGF-β) receptor family, underlie the 
majority of familial cases of pulmonary arterial hypertension (PAH). The TGF-β1 pathway is 
activated in PAH and inhibitors of TGF-β1 signaling prevent the development and progression of 
PAH in experimental models. However, the effect of currently utilized therapies on the TGF-β 
pathway is not known.  
Prostacyclin analogues remain the first line of treatment for clinical PAH. We hypothesized that 
these agents effectively decrease the activity of the TGF-β1 pathway. Beraprost sodium (BPS), a 
prostacyclin analogue selectively inhibits proliferation in a dose-dependent manner in mouse 
primary pulmonary arterial smooth muscle cells (PASMCs) harbouring a pathogenic BMPR2 
nonsense mutation in both the presence and absence of TGF-β1 stimulation. This study 
demonstrates that this agent inhibits TGF-β1–induced SMAD-dependent and -independent 
signaling via a PKA dependent pathway by reducing the phosphorylation of SMADs 2 and 3 and 
p38MAPK proteins. Finally, in a monocrotaline (MCT)-induced rat model of PAH, which is 
associated with increased TGF-β signaling, this study confirms that treprostinil (TPS), a stable 
prostacyclin analogue, inhibits the TGF-β pathway by reducing SMAD3 phosphorylation.  
Taken together, these data suggest that prostacyclin analogues inhibit dysregulated TGF-β 
signaling in vitro and in vivo and reduce BMPR-II-mediated proliferation defects in mutant mice 
PASMCs. 
Key words 
PAH, BMPR2, TGF-β signaling, prostacyclins and PASMC
 3 
Introduction 
 
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder caused by 
extensive vascular remodeling of blood vessels in the lung and in the absence of effective 
therapy, leads to right-heart failure and death. The major features of this disorder include 
increased resistance in the small pulmonary arteries and vascular remodeling due to abnormal 
proliferation of endothelial and pulmonary arterial smooth muscle cells (PASMCs). Loss-of-
function mutations in the type II bone morphogenetic protein receptor (BMPR-II), a member of 
the transforming growth factor- (TGF-) superfamily, underlie the majority (>80%) of cases of 
familial PAH (1), (2), identified an important role for TGF- signaling  in the development of 
PAH.  
 
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily of cytokines 
required for cellular differentiation and mammalian development. Activation of the receptor 
complex by ligand stimulation generates a phosphorylation relay of cytoplasmic signaling 
proteins, including the SMAD family capable of transducing the downstream signaling pathways. 
BMPs signal through a specific set of regulatory SMADs namely SMAD 1, 5 and 9, whilst TGF-
β-mediated signaling occurs via SMAD2/3 proteins.  On activation, these regulatory SMADs 
translocate to the nucleus in complex with co-SMAD (SMAD4) to directly regulate gene 
transcription (3). BMPs and TGF-β have also been reported to activate SMAD independent 
signaling including ERK, JNK and p38MAPK (4), (5-9).    
 
To gain further insight as to the pathogenesis of PAH, we and others have investigated the 
functional consequences of BMPR2 mutation. In cell-based studies, mutations in the BMPR2 gene 
have been shown to disrupt the BMP-induced SMAD1/5 pathway (10), (11). In animal models, 
mice deficient in BMPR-II (p.R899X) showed increased susceptibility to pulmonary hypertension 
and vascular remodeling, suggesting a link between dysfunctional BMPR-II signaling and PAH 
(8). In addition, an increasing number of studies suggest the involvement of TGF- signaling in 
PAH. In vitro, TGF-β1 elicits a pro-proliferative response in PASMCs isolated from PAH 
patients (PAH-PASMCs) compared to controls (12). Elevated TGF-β signaling has been 
implicated in a number of preclinical PAH models, including the aorto-pulmonary shunt model in 
lambs (13), hypoxia-induced PAH in mice and the monocrotaline (MCT)-induced model in rats 
(14). In addition, phosphorylation of SMAD2, a cytoplasmic signaling protein downstream of the 
TGF- receptor 1 (ALK 5), is increased in plexiform lesions from PAH patients (15). Taken 
together, these data suggest a role for activated TGF-β signaling in the pathogenesis of PAH and 
present the potential of targeting this pathway in PAH for therapeutic intervention (16). However, 
the molecular mechanisms by which TGF-β signaling is activated consequent to impaired BMPR-
II signaling have not been investigated and the impact of current therapies on these pathways 
remains unknown.  
 
Prostacyclin therapy has significant beneficial effects in patients with severe PAH, and this has 
been examined in an experimental animal model and human PASMCs. In the monocrotaline-
induced rat model, administration of beraprost sodium (BPS) significantly improved PAH, right 
ventricular hypertrophy, and pulmonary medial thickness without any adverse effects (17). 
Prostacyclin analogues have also been shown to inhibit serum/PDGF-induced PASMC 
proliferation via a cyclic adenosine monophosphate (cAMP)-dependent pathway (18). In 
fibroblasts and the skin of scleroderma patients, iloprost has been shown to suppress TGF-β–
induced expression of collagen and connective tissue growth factor (CTGF) genes via PKA-
dependent mitogen activated protein kinase (MAPK) pathways (19),
 
(20), suggesting a potential 
interaction between prostanoids and TGF-β signaling. The involvement of activated TGF- 
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signaling in the pathogenesis of PAH led us to hypothesize that prostacyclin analogues may also 
inhibit activated TGF- signaling in PAH.  
 
In this report, we investigate the beneficial effects of prostacyclin analogues on proliferation and 
TGF- signaling in mouse primary PASMCs harbouring a pathogenic nonsense mutation in the 
BMPR2 gene. We show that prostacyclin analogues inhibit the pro-proliferative phenotype in 
both the presence and absence of TGF-1 stimulation. Furthermore, we observe that prostanoids 
inhibit TGF-1–induced SMAD-dependent and -independent MAPK pathways by reducing the 
phosphorylation of SMAD3 and p38 MAPK proteins. Finally, we demonstrate that prostacyclin 
analogues inhibit the overactive TGF- pathway in the monocrotaline-induced PAH rat model.  
  
Materials and Methods 
 
Supporting Information contains full experimental details. 
 
Cell culture, transient transfection, enzymatic assay and western blots  
Cell culture and transfections were carried out as described elsewhere (21), (22). Mouse PASMCs 
were derived from wild type (bmpr2
+/+
) and knock-in mice (bmpr2 
R899X+/-
) harbouring a disease-
associated nonsense mutation (p.R899X) in the bmpr2 gene.  Luciferase and β-galactosidase 
activities were determined with the Dual-light Reporter Assay systems (Applied Biosystems) 
using an ORION-II Plate Luminometer (Berthold) according to manufacturers protocols. SMAD-
responsive reporter assay in mammalian cells was performed as previously described (21).  
Western blots were carried out using anti-phospho specific p38MAPK (Thr180/Thr182), SMAD2 
(Ser245/250/255) and SMAD3 (Ser463/465) (Cell Signaling) antibodies following 
manufacturer’s protocols. To confirm equal loading the membranes were stripped and re-probed 
with anti-β-actin antibody (Cell Signaling). 
 
Quantification of proliferation and cyclic AMP (c-AMP) production of mouse primary 
PASMCs 
To determine proliferation, PASMCs were seeded at 0.2X10 
5
 per well in a clear 96 well plate in 
DMEM containing 10% FBS. After 24 hours, the medium was replaced by either fresh 
DMEM/0.1% FBS alone or containing TGF-β1 (10ng/ml) (R&D Systems), SD208 (10µM) 
(TOCRIS), SB203580 (0.1-10 µM) (TOCRIS), or BPS (0.5-20 µM) (Cayman Chemicals) for 3-4 
days. Cell proliferation was determined using CellTiter 96
®
 Aqueous One Solution Cell 
Proliferation Assay (Promega) following the manufacturer’s protocol. Absorbance was recorded 
at 490nm using Omega Plate Reader (BMG Labtech). Production of cAMP was determined using 
the luminescence-based cAMP-Glo 
TM
 Assay kit (Promega) following the manufacturer’s 
protocol. Luminescence was determined using ORION-II plate Luminometer (Berthold). 
The monocrotaline induced PAH rat Model  
Male Sprague-Dawley rats (Charles River, Sulzfeld, Germany) either received a single injection 
of monocrotaline (MCT, 60 mg/kg, s.c.) or saline. Three weeks after MCT injection, osmotic 
minipumps containing treprostinil (0.15 mg/mL; to deliver an approximate rate of 45 ng/kg/min) 
or saline vehicle were implanted for a further 2 weeks. Six animals were used per group. 
RNA isolation, cDNA synthesis and reverse transcriptase PCR (RT-PCR) 
Frozen lung tissue was homogenized
 
and total RNA extracted with Trizol
 
reagent (Invitrogen) 
according to the manufacturer’s instructions. DNA was removed by TURBO DNA-free TURBO 
DNase treatment and removal reagents (Ambion). Reverse transcription was then performed
 
with 
 5 
the StrataScript first-strand synthesis system (Stratagene). Quantitative-PCR was performed using 
SYBR1 Green ER qPCR SuperMix, and samples were run on ABI step one machine.  
 
Statistical Analysis 
Analysis of data was carried out using the JMP software. The data was expressed as mean + SD 
and analyzed using the student’s T-test. One way analysis of variance (ANOVA) followed by 
Tukey’s post hoc tests were carried out for comparision of multiple means.  A P-value of < 0.05 
indicated statistical significance. 
 
 
Results 
  
Beraprost sodium (BPS) inhibits excessive cell proliferation in mutant mouse PASMCs  
Abnormal proliferation is a characteristic feature of the vascular remodeling observed in PAH. 
Therefore, the impact of a prostacyclin analogue beraprost sodium (BPS) on cellular proliferation 
was investigated in mouse primary PASMCs harbouring a disease causing BMPR2 nonsense 
mutation (bmpr2 
R899X+/-
). The mutant PASMCs proliferated more rapidly compared to wild-type 
(Figure 1A). Treatment with BPS inhibited proliferation in a dose-dependent manner and its anti-
proliferative effects were higher in mutant PASMCs than in wild-type at the three highest doses 
used (Figure 1B). Next, we investigated whether BPS treatment increased cAMP production in 
these cells using the luminescence-based cAMP-Glo 
TM
 Assay kit (Promega). The luminescence 
generated in this assay is inversely proportional to the cAMP levels.  BPS treatment inhibited 
luminescence activity in both wild-type and bmpr2 
R899X+/-
 PASMCs and this effect was higher in 
bmpr2 
R899X+/-
 cells compared with the wild-type (Figure 1C) suggesting that BPS-mediated 
cAMP production was higher in mutant cells.   
 
We recently reported that the expression of plasminogen activator inhibitor (PAI-1), a recognized 
target of TGF-β signaling (23) was increased in mutant cells compared to the wild-type adding 
weight to the evidence for overactive TGF-β signaling in the mutant cells (24). Neither the 
expression of TGF-β1 ligand and nor the type II TGFBR2 receptor was altered in either cell type 
(Supplementary Figure 1 A-B) and BPS exhibited no discernible effect on the expression of these 
genes in both wild type and bmpr2 
R899X+/- 
PASMCs (Supp. Fig. 1C-D).   
 
Beraprost restricts TGF-–induced, pro-proliferative activity in BMPR2-deficient PASMCs 
The effect of TGF-β1 ligand stimulation on the proliferation of bmpr2+/+ and bmpr2 R899X+/- 
PASMCs was examined. TGF-β1 was observed to have opposing effects on these cells, 
promoting proliferation in bmpr2 
R899X+/-
  cells in a dose-dependent manner, while showing no 
significant level of  inhibition of proliferation in bmpr2
+/+ 
cells (Figure. 2A). The pro-proliferative 
effect of TGF-β1 in bmpr2 R899X+/-  cells is abrogated by the TGF- signaling inhibitor (ALK5 
inhibitor), SD208 (Figure 2B). In addition, the p38MAPK inhibitor, SB203580 significantly 
reduced TGF-β1 stimulated proliferation of bmpr2 R899X+/-   PASMCs (Figure 2C). Of note, both 
SD208 and SB203580 had previously been found to inhibit basal level of proliferation of mutant 
cells (24).  Finally, BPS treatment also inhibited TGF-β1–stimulated proliferation of mutant 
PASMCs (Figure 2D).  
 
BPS inhibits TGF-β-stimulated SMAD-responsive reporter activity 
Next, the inhibition of TGF- activity by BMPR2 was investigated using a SMAD3 responsive 
SBE-Luc reporter assay in HEK293 cells (25). The overexpression of TGFBRII and TGF-1 
stimulation increased the reporter activity supporting the validity of this assay system (Supp 2A-
B). The expression of wild-type BMPR-II reduced TGF-–induced reporter activation, suggesting 
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a negative feedback loop between these two pathways (Figure 3A).  Expression of BMPR-II with 
pathogenic mutations in the ligand binding (p.C118W) and kinase (p.C347Y and p.D485G) 
domains resulted in a failure to attenuate TGF- activity. However, the expression of each mutant 
receptor showed differential effects on TGF--induced reporter activity compared with the wild-
type. The anti-TGF-effect of the p.D485G and p.C118W mutant receptors was significantly 
reduced compared with the wild type whilst p.C347Y mutant receptor showed no significant 
effect.  
 
Next, the effect of BPS treatment on the TGF-β pathway was measured. BPS inhibited both basal 
(Figure 3B) and TGF-β1–stimulated (Figure 3C) SBE-Luc reporter activity in HEK293 cells in a 
dose-dependent manner. Furthermore, the expression of constitutively active TGF-β receptor type 
II (TGFBRII) increased reporter activity, and BPS inhibited this activation (Figure 3D). These 
findings suggest that BPS-mediated inhibition of TGF-β activity is mediated via a SMAD3/4-
dependent pathway. BPS-mediated reporter inhibition of TGF-β signaling was reversed by a PKA 
inhibitor (KT5720) in the presence of TGFBRII overexpression (Figure 3E) and TGF-β1 ligand 
stimulation (Figure 3F) in a dose-dependent manner. Of note, the compound KT5720 has also 
been found to elicit non-specific effects on other protein kinases (26). Taken together, these data 
imply that the inhibitory effect of BPS on SMAD pathways may be PKA dependent.  
 
Effect of prostacyclin analogues and other targeted PAH therapies on TGF-β signaling 
 
Various prostacyclin analogues including BPS, treprostinil and iloprost exhibit differential 
therapeutic efficacy. We therefore investigated their individual effects on TGF- signaling. All 
three prostacyclin analogues significantly inhibited both TGFBRII and TGF-1-mediated SBE-
Luc reporter activation (Figure 4A-B). As a representation of the targeted PAH therapies, the 
effect of PDE5 inhibitor sildenafil citrate on TGF- signaling was investigated. This PDE5 
inihibitor attenuated TGFBR2-mediated reporter activation at a high concentration (10μM) but 
failed to inhibit the reporter activity at the lower concentration and had no effect on TGF-1-
mediated reporter activation 
     
Phosphorylation of SMAD3 is inhibited by BPS  
To confirm that BPS inhibited SMAD-dependent TGF- signaling, the phosphorylation of 
SMAD3 was examined by Western blot analysis. It was found that TGF-β1 stimulation increased 
the phosphorylation of SMAD3, and that BPS inhibited this phosphorylation in HEK293 cells 
(Figure 5A). TGF-1–stimulated SMAD3 phosphorylation is also increased in bmpr2 R899X+/-   
PASMCs compared to bmpr2
+/+  
cells, and BPS treatment inhibited this TGF-1 induced SMAD3 
phosphorylation in both cell types (Figure 5B-C). Furthermore, phosphorylation of the linker 
region of SMAD2 was found to be reduced following BPS treatment (Figure 5D). 
 
The pro-proliferative response of TGF-1 is also mediated via the SMAD-independent 
p38MAPK pathway and inhibited by BPS treatment 
Next, the effect of BPS on the TGF-–mediated SMAD-independent pathway was investigated. 
In bmpr2 
R899X+/-
   PASMCs, the basal level of p38MAPK phosphorylation was increased 
compared to wild-type PASMCs (Figure 6A-B). Stimulation of the cells with TGF-β1 ligand 
further activated p38MAPK phosphorylation in bmpr2 
R899X+/-
   cells, and BPS treatment 
significantly inhibited TGF-β1–induced p38MAPK phosphorylation in a dose-dependent manner 
(Figures 6A-B). In HEK293 cells, the overexpression of TGFBRII increased phosphorylation of 
p38MAPK, and both BPS and TPS reduced this phosphorylation (Figure 6C). In these cells, both 
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BPS and TPS treatments elicited no discernible effects on the expression of total p38MAPK as 
well as SMAD2/3 proteins (Supp. Fig. 3) 
 
Treprostinil (TPS) inhibits the TGF-–induced SMAD pathway in monocrotaline-induced 
PAH rat lungs  
The therapeutic potential of treprostinil (TPS), a stable prostacyclin analogue, was investigated in 
the MCT-induced PAH rat model which exhibited severe elevation of right ventricular systolic 
pressure, elevated pulmonary vascular resistance, and right ventricular hypertrophy and TPS 
treatment inhibited the progression of disease in these MCT-induced rats (27) .Western blot 
analysis of rat lungs following exposure to monocrotaline showed significantly increased SMAD3 
phosphorylation, which was inhibited upon TPS treatment (Figure 7A-B). In these extracts, TPS 
treatment exerted no discernible effects on the expression of total SMAD3 protein (Supp. Fig. 
4A-B). An elevated level of PAI-1 transcripts was observed in PAH rat lungs which was reduced 
following TPS treatment (Figure 7C).  
 
Discussion 
In this study, we provide insight into the mechanisms by which prostacyclin analogues inhibit 
BMPR-II-mediated proliferation defects that lead to the eventual vascular remodeling observed in 
PAH. We further demonstrate that BMPR2 mutation potentiates TGF-–mediated SMAD-
dependent and -independent pathways. Prostanoids inhibit TGF- signaling by inhibiting SMAD3 
and SMAD-independent p38MAPK pathways. To the best of our knowledge, this is the first 
report demonstrating a potential mechanism by which prostacyclin analogues inhibit overactive 
TGF- responses in PAH.   
 
Elevated expression levels of TGF- ligands have been reported in the serum of PAH patients 
(28) and in experimental models of PAH (29), (30), suggesting a link between the TGF- 
pathway and PAH. We have demonstrated that the expression of BMPRII receptor attenuated 
TGF- activity and this anti- TGF- effect is diminished in cells expressing mutant receptors 
deficient in kinase activity (p. D485G) or cell-surface localization (p.C118W) (10), suggesting 
that defects in BMPR2 receptor may potentiate TGF-signaling It has not escaped our attention 
that the p.D485G mutant receptor but not the p.C347Y mutant activated the SBE-Luc reporter 
activity. The p.D485G mutant receptor showed no receptor activity (21) whilst the p.C347Y 
mutant elicited a reduced level of SMAD1/5 activity (31) implying that there may be a correlation 
between the level of BMPR2 receptor deficiency and the activation of TGF-signaling. We have 
shown in a number of ways that the activation of the TGF- pathway contributes to abnormal 
proliferation via SMAD-independent p38MAPK in PASMCs deficient in BMPR-II receptor. 
First, we have demonstrated that TGF-1 stimulation promotes proliferation in bmpr2 R899X+/-   
PASMCs in a dose-dependent manner. Second, we show that in the wild-type PASMCs, this 
ligand does not increase proliferation but significantly enhances phosphorylation of SMAD3 
protein indicating that the TGF--inducedpro-proliferative activity in mutant cells is mediated 
via SMAD-independent pathways (24, 32). Third, we have shown that selective inhibition of 
p38MAPK using the small molecule inhibitor SB203580 inhibits the pro-proliferative response to 
TGF-1 ligand in these mutant cells in a dose-dependent manner.   
 
Emerging evidence supports the role of p38MAPK in the pathogenesis of pulmonary vascular 
remodeling, a process that has been shown to be regulated by BMPs and TGF-s, cellular stress 
and inflammatory cytokines (33). Hypoxia induces p38MAPK phosphorylation in pulmonary 
arteries and induces proliferation of human PASMCs (34). Inhibition of this pathway reverses 
hypoxia-induced pulmonary arterial dysfunction, including endothelium-dependent relaxation (5)
,
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(9). Transfection of mutant, but not wild-type, BMPR2 constructs activates p38MAPK 
phosphorylation in a mouse epithelial cell line (NMuMG), generating a pro-proliferative response 
(10). PAH-PASMCs harbouring a number of BMPR2 mutations showed enhanced p38MAPK 
phosphorylation in response to BMP4 stimulation (35), supporting the involvement of this 
pathway in PAH. However, targeting the TGF-/p38MAPK axis carries substantial risk due to its 
role in maintaining normal homeostasis. Therefore, the inhibition of this pathway requires a 
deeper understanding of TGF- signaling and the context in which it acts, as well as the cellular 
consequences of its inhibition. 
 
As prostacyclin therapy remains the first line treatment for patients with severe PAH, the mode of 
action of these drugs in mouse and human PASMCs and in the monocrotaline-induced PAH rat 
model was investigated. Several lines of evidence are provided that suggest that prostacyclin 
analogues are capable of inhibiting TGF-–induced SMAD-dependent and -independent 
pathways in mouse primary PASMCs and PAH-PASMCs. First, it was demonstrated that 
beraprost sodium inhibits abnormal cell proliferation in mouse PASMCs in a dose-dependent 
manner in both the absence and presence of TGF- stimulation. Second, it was shown that the 
drug is capable of inhibiting TGF-1–induced SMAD-independent p38MAPK phosphorylation in 
mouse PASMCs and TGFBRII-induced p38MAPK phosphorylation in HEK293 cells. Third, 
evidence was provided that this chemical inhibits the TGFβ-SMAD axis by inhibiting the 
phosphorylation of SMAD 3 protein in these cells. Finally, in vivo support of the in vitro findings 
was provided in the monocrotaline-induced PAH rat model, in which the expression of BMPR-II 
receptor is reduced and the TGFβ pathway is activated (14), (24). In the MCT-induced rat model, 
treprostinil infusion attenuated over-active TGF-1 signaling by inhibiting the phosphorylation of 
SMAD3. It remains unknown as to how prostacyclin analogues elicit anti-TGF-activity. Our 
data suggest that this anti-TGF-effect may be mediated through the PKA-dependent pathway 
and the drug may modulate the activity of the TGFBRII receptor. However, further studies are 
required to understand the molecular mechanisms by which prostacyclin analogues interfere with 
TGF-signaling.   
 
Although prostacyclin-mediated vasodilator and anticoagulant activities are well described, the 
mechanisms by which these drugs exert their anti-proliferative effects are not well understood. 
Prostanoids have been shown to inhibit proliferation in PAH-PASMCs and this effect appears to 
be mediated via a PKA-dependent pathway (18), which is consistent with our observations. Our 
data suggest that the anti-proliferative effects of BPS may be mediated through the cAMP-PKA-
dependent pathway as the mutant cells produced an elevated level of cAMP and showed an 
enhanced anti-proliferative effect compared with control PASMCs in response to BPS. Together, 
these observations indicate that BMPR2 mutation may impair the prostacyclin- cAMP-PKA 
pathway which may contribute to the activation of TGF-signaling, and prostacyclin analogues 
exert anti- TGF-effects through the elevation of cAMP-PKA pathway. Increased plasma cAMP 
levels were observed in healthy subjects following prostacyclin inhalation (36) but the association 
between elevated cAMP levels and clinical outcome of PAH has not been established.  As G-
protein coupled receptor (GPCR)-mediated signaling and phosphodiesterase inhibitors raise the 
level of cAMP (37), it would be interesting to investigate whether they elicit anti-TGF-effects 
in PAH. Of note, the anti-proliferative effect of prostanoids has also been reported to be regulated 
through PKA-independent PPARγ and - pathways (38), (39). In PAH, the imbalance between 
TGF-β and BMP signaling events contributes to the initial stages of vascular remodeling (40) and 
thus a balance between these two pathways may provide a target for therapeutic intervention.  We 
demonstrated previously that prostacyclins restore the balance in part through the elevation of 
BMP signaling in PAH-PASMCs and in the monocrotaline-induced rat model which are 
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associated with reduced BMPR-II expression (27). Here, we show that these drugs also inhibit 
overactive TGF- signaling in mouse PASMCs harbouring a nonsense mutation in the BMPR2 
gene. Taken together, these data indicate that the benefits of these drugs may be stronger in 
patients with loss of function BMPR-II mutations.  
 
In conclusion, we have demonstrated that dysfunctional BMPR-II-mediated signaling leads to 
increased TGF- signaling, inducing both SMAD-dependent and -independent p38MAPK 
pathways, and that prostanoids play an essential role in fine tuning the effects of BMP and TGF- 
in the treatment of PAH. Given the preventative potential of these drugs in animal models (27), 
we propose that the inhibition of increased TGF- activity via prostacyclins may be an effective 
prophylactic intervention in PAH. 
 
Acknowledgements 
The authors express sincere thanks to Ms Bethan Jones for critically reading through the 
manuscript and Ms Seshu Kanneganti for technical assistance. This work was supported by a 
fellowship (awarded to MTN) from the Department of Health via the NIHR Comprehensive 
Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership 
with King’s College London and the Cambridge NIHR Biomedical Research Centre. The authors 
acknowledge financial support from the British Heart foundation, UK (programme grant 1-2004-
357 to RCT), and to NWM, Heptagon Life Science Proof of Concept Fund (grants KCL24 and 
KCL25 to MTN and RCT, respectively) and the Great Britain Sasakawa Foundation (B70 to 
MTN).   
 
Disclosures 
None. 
 
 
References 
1. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, 3rd, Loyd JE, Nichols 
WC, Trembath RC. Heterozygous germline mutations in bmpr2, encoding a tgf-beta receptor, 
cause familial primary pulmonary hypertension. The international pph consortium. Nat Genet 
2000;26:81-84. 
2. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, 
Janssen B, Koehler R, Seeger W, et al. Mutations of the tgf-beta type ii receptor bmpr2 in 
pulmonary arterial hypertension. Hum Mutat 2006;27:121-132. 
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-1544. 
4. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, 
Chen H, Trembath RC, Morrell NW. Dysfunctional smad signaling contributes to abnormal 
smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 
2005;96:1053-1063. 
5. Welsh DJ, Peacock AJ, MacLean M, Harnett M. Chronic hypoxia induces constitutive 
p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation 
in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care Med 
2001;164:282-289. 
6. Zeng Z, Li Y, Jiang Z, Wang C, Li B, Jiang W. The extracellular signal-regulated kinase 
is involved in the effects of sildenafil on pulmonary vascular remodeling. Cardiovasc Ther;28:23-
29. 
7. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood 
M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary 
hypertension in bmpr2-deficient mice. Circ Res 2006;98:818-827. 
 10 
8. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K. Mice 
expressing bmpr2r899x transgene in smooth muscle develop pulmonary vascular lesions. Am J 
Physiol Lung Cell Mol Physiol 2008;295:L744-755. 
9. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 mapk 
reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ 
Physiol 2009;296:H1312-1320. 
10. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath 
RC, Morrell NW. Functional analysis of bone morphogenetic protein type ii receptor mutations 
underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517-1525. 
11. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone 
morphogenetic protein receptor-ii mutants found in patients with primary pulmonary 
hypertension. Mol Biol Cell 2002;13:3055-3063. 
12. Atkinson C, Stewart S, Imamura T, Trembath RC, Morrell NW. Immunolocalisation of 
bmpr-ii and tgf-ss type i and ii receptors in primary plexogenic pulmonary hypertension. J Heart 
Lung Transplant 2001;20:149. 
13. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM. Alterations in 
tgf-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. 
Am J Physiol Lung Cell Mol Physiol 2003;285:L209-221. 
14. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered 
bone morphogenetic protein and transforming growth factor-beta signaling in rat models of 
pulmonary hypertension: Potential for activin receptor-like kinase-5 inhibition in prevention and 
progression of disease. Circulation 2009;119:566-576. 
15. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired 
transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J 
Respir Crit Care Med 2004;170:1340-1348. 
16. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. 
Altered growth responses of pulmonary artery smooth muscle cells from patients with primary 
pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. 
Circulation 2001;104:790-795. 
17. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a rho-kinase 
inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J 
Cardiovasc Pharmacol 2007;50:195-200. 
18. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin 
analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth 
muscle cells. Circulation 2000;102:3130-3136. 
19. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black 
CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts 
and in the skin of scleroderma patients. J Clin Invest 2001;108:241-250. 
20. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, 
Leask A. Prostacyclin derivatives prevent the fibrotic response to tgf-beta by inhibiting the 
ras/mek/erk pathway. FASEB J 2002;16:1949-1951. 
21. Nasim MT, Ghouri A, Patel B, James V, Rudarakanchana N, Morrell NW, Trembath RC. 
Stoichiometric imbalance in the receptor complex contributes to dysfunctional bmpr-ii mediated 
signalling in pulmonary arterial hypertension. Hum Mol Genet 2008;17:1683-1694. 
22. Nasim MT, Eperon IC. A double-reporter splicing assay for determining splicing 
efficiency in mammalian cells. Nature Protocols 2006;1:1022-1028. 
23. Thomas M, Docx C, Holmes AM, Beach S, Duggan N, England K, Leblanc C, Lebret C, 
Schindler F, Raza F, et al. Activin-like kinase 5 (alk5) mediates abnormal proliferation of 
vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is 
 11 
involved in the progression of experimental pulmonary arterial hypertension induced by 
monocrotaline. Am J Pathol 2009;174:380-389. 
24. Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN, Rhodes C, Trembath RC. Bmpr-
ii deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of 
tgfbeta-tak1-mapk pathways in pah. Hum Mol Genet;21:2548-2558. 
25. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of smad3 
and smad4 to critical tgf beta-inducible elements in the promoter of human plasminogen activator 
inhibitor-type 1 gene. Embo J 1998;17:3091-3100. 
26. Murray AJ. Pharmacological pka inhibition: All may not be what it seems. Sci Signal 
2008;1:re4. 
27. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, 
Schermuly RT, Morrell NW. Smad-dependent and smad-independent induction of id1 by 
prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and 
in vivo. Circ Res;107:252-262. 
28. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth 
factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 
2009;34:662-668. 
29. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in 
rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem 
Pharmacol 1993;46:1086-1091. 
30. Jiang Y, Dai A, Li Q, Hu R. Hypoxia induces transforming growth factor-beta1 gene 
expression in the pulmonary artery of rats via hypoxia-inducible factor-1alpha. Acta Biochim 
Biophys Sin (Shanghai) 2007;39:73-80. 
31. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A, Upton PD, Trembath 
RC, Morrell NW. Mutations in bone morphogenetic protein type ii receptor cause dysregulation 
of id gene expression in pulmonary artery smooth muscle cells: Implications for familial 
pulmonary arterial hypertension. Circ Res 2008;102:1212-1221. 
32. Davies RJ, Holmes AM, Deighton J, Long L, Yang X, Barker L, Walker C, Budd DC, 
Upton PD, Morrell NW. Bmp type ii receptor deficiency confers resistance to growth inhibition 
by tgf-beta in pulmonary artery smooth muscle cells: Role of proinflammatory cytokines. Am J 
Physiol Lung Cell Mol Physiol;302:L604-615. 
33. Massague J. Integration of smad and mapk pathways: A link and a linker revisited. Genes 
Dev 2003;17:2993-2997. 
34. Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery 
smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol 
Physiol 2009;297:L1151-1159. 
35. Dewachter L, Adnot S, Guignabert C, Tu L, Marcos E, Fadel E, Humbert M, Dartevelle 
P, Simonneau G, Naeije R, et al. Bone morphogenetic protein signalling in heritable versus 
idiopathic pulmonary hypertension. Eur Respir J 2009;34:1100-1110. 
36. Beghetti M, Reber G, de MP, Vadas L, Chiappe A, Spahr-Schopfer I, Rimensberger PC. 
Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 
2002;19:518-524. 
37. Pullamsetti SS, Savai R, Schaefer MB, Wilhelm J, Ghofrani HA, Weissmann N, Schudt 
C, Fleming I, Mayer K, Leiper J, et al. Camp phosphodiesterase inhibitors increases nitric oxide 
production by modulating dimethylarginine dimethylaminohydrolases. Circulation 
2011;123:1194-1204. 
38. Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH. Smooth 
muscle proliferation and role of the prostacyclin (ip) receptor in idiopathic pulmonary arterial 
hypertension. Am J Respir Crit Care Med;182:1161-1170. 
 12 
39. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, Bishop-Bailey D, Warner TD, 
Mitchell JA. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors 
in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 2006;34:242-246. 
40. ten Dijke P, Arthur HM. Extracellular control of tgfbeta signalling in vascular 
development and disease. Nat Rev Mol Cell Biol 2007;8:857-869. 
 
 
Figure legends 
 
Figure 1 
Inhibition of abnormal cell proliferation by beraprost sodium (BPS) and effect on cAMP 
production. Twenty four  hours after seeding wild-type (WT bmpr2 
+/+)
 and mutant (bmpr2 
R899X+/-
) mouse primary PASMCs, the medium was replaced with DMEM/0.1%FCS with or without 
BPS and following incubation for 3-4 days proliferation was measured using the CellTiter 96
®
 
Aqueous One Solution Cell Proliferation Assay (Promega) (A,B), in the presence of increasing 
concentrations of BPS (B) or cAMP production measured using the cAMP Glo Assay kit 
(Promega) in the presence or absence of 10µM BPS (C). The luminescence generated in the 
cAMP Glo assay is inversely proportional to the cAMP levels. White bars/diamonds represent 
wild-type cells and filled black bars/squares represent mutant PASMCs. Results shown as a 
percentage of wild-type (A), or as a percentage of untreated cells (B, C). * - p < 0.05, ** - p < 
0.01, *** - p < 0.001. Data are presented as the mean ± SD from at least 3 independent 
experiments. 
 
 
Figure 2 
The pro-proliferative response of TGF-β1 is inhibited by BPS. Proliferation was measured as in 
Fig 1 after mouse wild type (white bars) and/or mutant (black bars) PASMCs were incubated in 
DMEM/0.1% FCS for 3-4 days in the presence and absence of (A) increasing concentrations of 
TGF1, (B) ALK5 inhibitor, SD208 (10µM), (C) increasing concentrations of p38 MAPK 
inhibitor, SB203580 in the presence of 10ng/ml TGF-β1 and (D) increasing concentrations of 
BPS in the presence of 10ng/ml TGF-β1. All results expressed as a percentage of untreated cells. 
NS – non significant, * - p < 0.05, ** - p < 0.01, *** - p < 0.001. Data are presented as the mean 
± SD from 3-6 independent experiments. 
 
Figure 3 
Inhibition of SMAD responsive reporter activity by beraprost. Transient transfections of reporter 
plasmids with or without additional plasmids containing either the wild-type or mutated BMPR2 
or TGFBRII in HEK293 cells. Twenty four hours after transfection, the medium was replaced by 
DMEM/0.1% FCS in the presence or absence of TGF-β1 and/or BPS or KT5720 and incubated 
for a further 16 hours. Luciferase and β-Galactosidase activities were measured using the Tropix 
Dual Light Assay (Applied Biosystems).   The luc/gal ratio of untreated cells with no additional 
plasmids was set as 100. (A) Cells transfected with reporter plasmids only (control) or reporter 
plasmids together with a plasmid encoding either wild-type BMPR2 or mutated BMPR2 
(pC118W, pC347Y and pD485G) in the presence or absence of 10ng/ml of TGF-β1. Transfection 
of reporter plasmids in the presence of increasing concentrations of BPS in the absence (B) and 
presence of 10ng/ml TGF-β1 stimulation (C). (D) Cells transfected with reporter plasmids and a 
plasmid containing the wild-type TGFBRII or stimulated with 10ng/ml TGF-β1in the presence or 
absence of 10µM BPS. As in (D), in the presence of increasing concentrations PKA inhibitor 
KT5720 in cells overexpressed with TGFBRII receptor  (E) and stimulated with TGF1 (F). NS – 
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non significant, * - p < 0.05, ** - p < 0.01, *** - p < 0.001, compared to untreated controls unless 
otherwise indicated. Data are presented as the mean ± SD from 3-6 independent experiments. 
 
Figure 4 
 
Inhibition TGF-β signaling by prostacyclin analogues and PDE5 inhibitor, sildenafil citrate. 
As in Fig 3(D), following treatment with prostacyclin analogues Beraprost Sodium (BPS), 
Treprostinil (TPS) and Iloprost (ILO) and the PDE5 inhibitor Sildenafil citrate (PDE5) at 
concentrations of 10µM and 1µM as well as SD208 (10µM) in the presence of TGFBRII 
overexpression  (A) and  (B) TGF-β1 stimulation. The recognised ALK5 inhibitor SD208 was 
used as a positive control. The Luc/Gal ratio of untreated cells was set as 100. NS – non 
significant, * - p < 0.05, ** - p < 0.01, *** - p < 0.001, in comparison with untreated cells. Data 
are presented as the mean ± SD from 3 independent experiments. 
 
Figure 5 
BPS inhibits SMAD3 phosphorylation (Ser423/425) in HEK293 and mouse primary PASMCs.   
(A) Phospho-SMAD3 levels in HEK293 cells were detected by western blot with and without one 
hour of TGF-β1stimulation in the presence of increasing concentrations of BPS. (B) Phospho-
SMAD3 levels in wild-type (WT bmpr2 
+/+
) and mutant (bmpr2 
R899X+/-
) mouse primary PASMCs 
were detected by western blot in the presence and absence of 10ng/ml TGF-β1 and 1, 5 and 10µM 
BPS.  (C) Quantification of phospho-SMAD3 levels relative to β-actin from wild-type (white 
bars) and mutant (black bars) PASMCs derived from three independent experiments. * - p < 0.05, 
** - p < 0.01 compared with TGF-β1stimulated cells. Western blot of phosphorylated SMAD2 
(Ser245/250/255) in the presence and absence of TGF-β1(10ng/ml) and 10µM BPS in mutant 
PASMCs. 
 
Figure 6 
Inhibition of SMAD-independent p38MAPK pathways by BPS treatment. (A) Phosphorolated-
p38MAPK levels in wild-type (WT bmpr2 
+/+ 
) and mutant (bmpr2 
R899X+/-
) mouse primary 
PASMCs were detected by western blot in the presence and absence of 10ng/ml TGF-β1 and 1, 5 
and 10µM BPS. (B) Quantification of phosphorylated-p38MAPK levels relative to β-actin from 
wild-type (white bars) and mutant (black bars) PASMCs derived from three independent 
experiments. (C) Phosphorolated-p38MAPK levels in HEK293 cells were detected by western 
blot following TGFBRII overexpression in the presence and absence of BPS and TPS treatment. * 
- p < 0.05, ** - p < 0.01 compared with untreated or TGF-β1stimulated cells. 
 
Figure 7 
Inhibition of TGF-β signaling in monocrotaline (MCT)-induced PAH rat lungs by treprostinil 
(TPS) treatment. (A) Phospho-SMAD3 levels were detected by western blot in rat lungs 
following two weeks of treatment with MCT or MCT and TPS. (B) Quantification of phospho-
SMAD3 levels relative to β-actin. (C) Relative expression of PAI-1 to β-actin transcripts in rat 
lungs following two weeks of treatment with MCT or MCT and TPS. * - p < 0.05, ** - p < 0.01 
compared with control. 
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